What are the indications, recommended dosing, contraindications, and monitoring parameters for losartan in adult patients?

Losartan: Indications, Dosing, Contraindications, and Monitoring

Indications

Losartan is indicated for hypertension, hypertensive patients with left ventricular hypertrophy (to reduce stroke risk), and nephropathy in type 2 diabetic patients. 1

• Hypertension: Losartan is recommended as a first-line agent for blood pressure lowering, typically in combination with a dihydropyridine calcium channel blocker or thiazide/thiazide-like diuretic 2
• Left ventricular hypertrophy: Used specifically in hypertensive patients to reduce cardiovascular morbidity and mortality, particularly stroke 2, 1
• Diabetic nephropathy: Indicated for type 2 diabetic patients with proteinuria to provide renal protection 1

Recommended Dosing

Adult Hypertension

The usual starting dose is 50 mg once daily, with titration up to 100 mg once daily based on blood pressure response. 1

• Start at 25 mg once daily in patients with possible intravascular depletion (e.g., those on diuretic therapy) 1
• Maximum dose: 100 mg once daily 1
• Addition of hydrochlorothiazide 12.5 mg to losartan 50 mg produces additive blood pressure reductions of 15.5/9.2 mmHg 1, 3
• Dosing can be once or twice daily; twice-daily dosing provides larger trough responses than once-daily at the same total dose 1
• Can be taken without regard to food 4

Hypertensive Patients with Left Ventricular Hypertrophy

Start with 50 mg once daily, add hydrochlorothiazide 12.5 mg daily, then increase losartan to 100 mg once daily followed by hydrochlorothiazide 25 mg daily based on blood pressure response. 1

Nephropathy in Type 2 Diabetic Patients

Start with 50 mg once daily and increase to 100 mg once daily based on blood pressure response. 1

• Research demonstrates that 100 mg daily is more effective than 50 mg for renoprotection, reducing albuminuria by 48% versus 30%, without additional benefit at 150 mg 5

Pediatric Hypertension (≥6 years)

Starting dose is 0.7 mg/kg once daily (up to 50 mg total), with maximum dose of 1.4 mg/kg (not exceeding 100 mg daily). 1

• Not recommended in children <6 years or with eGFR <30 mL/min/1.73 m² 1

Hepatic Impairment

In mild-to-moderate hepatic impairment, start with 25 mg once daily. 1

• Losartan has not been studied in severe hepatic impairment 1

Contraindications and Precautions

Do not use losartan in combination with ACE inhibitors or direct renin inhibitors, in patients with history of angioedema with ARBs, or during pregnancy. 2, 1

Absolute Contraindications

• Pregnancy: Losartan causes serious fetal toxicity when given in second and third trimesters 4
• History of angioedema with ARBs 2
• Combination with other RAS blockers (ACE inhibitors or direct renin inhibitors) 2

Use with Caution

• Severe bilateral renal artery stenosis: Risk of acute renal failure 2
• Volume depletion/hypotension: Start with 25 mg dose 1
• Hyperkalemia risk: Increased in patients with CKD or those on potassium supplements/potassium-sparing drugs 2
• Moderate-to-severe renal impairment: Monitor closely, though no dose adjustment required 4

Important Safety Note

Do NOT initiate losartan in patients hospitalized with acute illness (e.g., pneumonia, COVID-19) due to significantly increased risk of hypotension and serious adverse events. 6

• In hospitalized COVID-19 patients, losartan increased serious adverse events (39.8% vs 27.2%) and hypotension (30.4% vs 15.3%) compared to usual care 6

Monitoring Parameters

Blood Pressure Monitoring

• Target systolic BP: 120-129 mmHg in most adults, provided treatment is well tolerated 2
• Recheck BP in 1 month after initiating therapy in stage 1 hypertension with high cardiovascular risk or stage 2 hypertension 2
• Peak effect occurs 6 hours post-dose; trough effect at 24 hours with trough-to-peak ratios of 50-95% for systolic and 60-90% for diastolic responses 1

Laboratory Monitoring

• Serum potassium: Monitor for hyperkalemia, especially in patients with CKD, on potassium supplements, or potassium-sparing diuretics 2
• Renal function (serum creatinine/eGFR): Particularly important in patients with renal impairment or bilateral renal artery stenosis 2
• Uric acid levels: When used with thiazide diuretics 2
• Albuminuria: In diabetic nephropathy patients to assess renoprotection 5

Clinical Monitoring

• Orthostatic vital signs: Especially in elderly patients (≥85 years), those with frailty, or at risk for volume depletion 2
• Adverse effects: Dizziness (most common adverse effect more frequent than placebo), headache, upper respiratory infection, asthenia/fatigue 1, 7
• Cough: Occurs in only 3.1% (similar to placebo 2.6%), much lower than ACE inhibitors 7

Key Clinical Pearls

• Pharmacokinetics: Losartan is rapidly absorbed with peak concentrations at 1-2 hours; approximately 14% is converted to the active E-3174 metabolite, which is 10-40 fold more potent with a half-life of 6-9 hours 4
• Drug interactions: Favorable profile with no clinically relevant interactions with hydrochlorothiazide, warfarin, or digoxin 4
• Not removed by hemodialysis 4
• Combination therapy preferred: Current guidelines recommend combination BP-lowering treatment for most patients with confirmed hypertension (BP ≥140/90 mmHg) as initial therapy, preferably with a RAS blocker plus dihydropyridine CCB or diuretic in a single-pill combination 2
• Lifelong treatment: Maintain BP-lowering therapy lifelong, even beyond age 85, if well tolerated 2